Association between inflammatory markers and the interleukin-6 -174 G/C polymorphism is abolished in peripheral arterial occlusive disease

International Angiology

Volumn 26, Issue 4, 2007, Pages 318-323

  Potaczek, D P ^a   Unidas, A ^a   Nowakowski, T ^a   Szczeklik, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Atherosclerosis; Genetic; Inflammation; Interleukin 6 Arterial occlusive disease; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; FIBRINOPEPTIDE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INFLAMMATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL;

ACUTE-PHASE PROTEINS; ADULT; ARTERIAL OCCLUSIVE DISEASES; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, GENETIC;

EID: 38949151073     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37.
2. Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6-type cytokines. Ann N Y Acad Sci 1995;762:1-14.
3. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001;103:2260-5.
4. Jenny NS, Tracy RP, Ogg MS, Luong le A, Kuller LH, Arnold AM et al. In the elderly, interleukin-6 plasma levels and the-174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:2066-71.
5. Chiappelli M, Tampieri C, Tumini E, Porcellini E, Caldarera CM, Nanni S et al. Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet 2005;32:349-53.
6. Sie MP, Sayed-Tabatabaei FA, Oei HH, Uitterlinden AG, Pols HA, Hofman A et al. Interleukin 6-174 G/C promoter polymorphism and risk of coronary heart disease. Results from the Rotterdam Study and a meta-analysis. Arterioscler Thromb Vasc Biol 2006;26:212-7.
7. Potaczek DP. Undas A, Szczeklik A. Interleukin-6 (IL-6)-174 G/C polymorphism: lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril. Int J Cardiol 2006;112:123-4.
8. Potaczek DP, Undas A, Celinska-Lowenhoff M, Szczeklik A. Interleukin-6-174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood Coagul Fibrinolysis 2006;17:35-8.
9. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000;85:1334-9.
10. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006;59:211-5.
11. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002;53:1029-34.
12. Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G et al. High circulating levels of cytokines (IL-6 and TNF.), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003;8:15-9.
13. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006;163:334-41.
14. Bertz L, Barani J, Gottsater A, Nilsson PM, Mattiasson I, Lindblad B. Are there differences of inflammatory biomarkers between diabetic and non-diabetic patients with critical limb ischemia? Int Angiol 2006;25:370-7.
15. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2005;29:171-6.
16. Elhadd TA, Kennedy G, Robb R, McLaren M, Jung RT, Belch JJ. Elevated soluble cell adhesion molecules E-selectin and intercellular cell adhesion molecule-1 in type-2 diabetic patients with and without asymptomatic peripheral arterial disease. Int Angiol 2004;23:128-33.
17. Flex A, Gaetani E, Pola R, Santoliquido A, Aloi F, Papaleo P et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg 2002;24:264-8.
18. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005;10:191-8.
19. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-38.
20. Grant PJ. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin 2005;21 Suppl 1:S5-S12.
21. Diamantopoulos EJ, Andreadis EA, Kakou MG, Vassilopoulos CV, Vlachonikolis IG, Gianna-Kopoulos NA et al. Association of the HLA antigens with early atheromatosis in subjects with type 2 diabetes mellitus. Int Angiol 2002;21:379-83.
22. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071-7.